New drug aims to slow Alzheimer's in chinese patients

NCT ID NCT07571161

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study tests donanemab, an experimental drug, against a placebo in 140 Chinese adults who show early signs of Alzheimer's risk. Participants receive the drug intravenously every few weeks for up to 3 years. The goal is to see if donanemab can delay memory loss and help maintain daily living skills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donanemab
What this could lead to: If it works, this could slow memory and function decline in early Alzheimer's, offering a new treatment option for Chinese patients.
What could go wrong: This is a Phase 3 trial, but results from other populations have been mixed. The drug may not work or could cause side effects like brain swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

2nd Affiliated Hospital Chongqing Medical University
NOT_YET_RECRUITING

Chongqing, 400010, China
Anhui Provincial Hospital
RECRUITING

Hefei, 230036, China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING

Fuzhou, 350001, China
Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, 201107, China
Jiangsu Province Official Hospital
RECRUITING

Nanjing, 210008, China
Jinan Central Hospital
RECRUITING

Jinan, 250100, China
Nanjing Brain Hospital
RECRUITING

Nanjing, 210029, China
Peking University Third Hospital
RECRUITING

Beijing, 100191, China
Pudong New Area People's Hospital Shanghai
RECRUITING

Shanghai, 201200, China
Qinghai Provincial People's Hospital
RECRUITING

Xining, 810007, China
Renji Hospital Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, 200127, China
Shaanxi provincial people's hospital
RECRUITING

Xi'an, 710068, China
Shanghai East Hospital
RECRUITING

Shanghai, 200120, China
Shanghai Sixth People's Hospital
RECRUITING

Shanghai, 200030, China
ShenZhen People's Hospital
RECRUITING

Shenzhen, 518020, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, 610072, China
Sir Run Run Hospital of Nanjing Medical University
RECRUITING

Nanjing, 211166, China
The First Affiliated Hospital of Chongqing Medical University
NOT_YET_RECRUITING

Chongqing, 400016, China
The First Affiliated Hospital of Nanyang Medical College
RECRUITING

Nanyang, 473061, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, 325027, China
The First Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, 050031, China
The First Hospital of Jilin University
RECRUITING

Changchun, 100012, China
The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, 330038, China
The Second Hospital of Jiaxing
RECRUITING

Jiaxing, 314000, China
Tianjin Medical University General Hospital
RECRUITING

Tianjin, 300052, China
Xiangya Hospital Central South University
RECRUITING

Changsha, 410008, China
Xianyang Hospital of Yan'an University
RECRUITING

Xianyang, 712000, China
Zigong First People's Hospital
RECRUITING

Zigong, 643000, China
Zunyi First People's Hospital
RECRUITING

Zunyi, 563002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.